Clinical Trial Update: Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of sunitinib, tamoxifen, and cisplatin for high-risk intraocular melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraocular Melanoma

Drugs mentioned

• Nolvadex (tamoxifen)
• Platinol (cisplatin)
• Sutent (sunitinib)

Snippet

Sponsor: San Diego Pacific Oncology & Hematology Associates | Conditions: Intraocular Melanoma | Phase 2 | Status: UNKNOWN